Docetaxel Adco 20 mg/1 ml, 80 mg/4 ml, 140 mg/7 ml Concentrate for solution for infusion
PDF Leaflet Revision Date: 16 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, prostate, and head and neck cancers.
Dosage (summary)
75-100 mg/mu00b2 IV infusion every 3 weeks, depending on cancer type and treatment regimen.
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects observed.
Key Drug Interactions
- CYP3A4 inhibitors/inducers
- Cisplatin
- Doxorubicin
Contraindications
- Severe hypersensitivity to docetaxel
- Neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Fluid retention
- Hypersensitivity reactions
- Peripheral neuropathy
Counselling Points
- Monitor for signs of infection
- Premedication with corticosteroids recommended
- Avoid pregnancy during treatment
Serious warnings
- Severe hypersensitivity reactions
- Fluid retention
- Increased risk of treatment-related mortality in liver impairment
Important Disclaimer
The Docetaxel Adco 20 mg/1 ml, 80 mg/4 ml, 140 mg/7 ml Concentrate for solution for infusion professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
